Thesis icon

Thesis

Predicting and understanding outcomes on first-line immunochemotherapy for oesophageal adenocarcinoma: Deep molecular profiling of the LUD2015-005 trial

Abstract:

Oesophageal adenocarcinoma (OAC) is a significant cause of cancer mortality that is rapidly rising in prevalence in many parts of the world. OAC is often inoperable at the time of diagnosis, and for these patients, the median survival on current first-line palliative treatment options is less than one year. Therefore, these patients represent a sizable population in need of additional treatment options. Recent phase III studies have shown that the addition of immune checkpoint inhibitors (...

Expand abstract

Actions


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Oxford college:
Magdalen College
Role:
Author

Contributors

Role:
Supervisor
Role:
Supervisor
More from this funder
Programme:
CRUK Centres Network Accelerator Grant
Funding agency for:
Middleton, M
Lu, X
Grant:
A21998
More from this funder
Programme:
Multimodal Cancer Therapies Theme. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
Funding agency for:
Middleton, M
Lu, X
More from this funder
Programme:
Departmental funding (for TC through Lu Lab) and additional funding for the LUD2015-005 trial (XL, MM)
Funding agency for:
Middleton, M
Carroll, T
Lu, X
More from this funder
Programme:
This research was conducted with support from AstraZeneca UK Limited, who provided durvalumab and tremelimumab for the LUD2015-005 trial.
Funding agency for:
Middleton, M
More from this funder
Funding agency for:
Carroll, T
Grant:
Rhodes Scholarship (Texas & Magdalen, 2016)
Type of award:
DPhil
Level of award:
Doctoral
Awarding institution:
University of Oxford

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP